检验医学 ›› 2013, Vol. 28 ›› Issue (7): 567-572.DOI: 10.3969/j.issn.1673-8640.2013.07.002

• 临床应用研究.论著 • 上一篇    下一篇

NT-proBNP对老年稳定型冠心病患者未来不良心脏事件风险评估价值

伍树芝   

  1. 湖南省老年医院检验科,湖南 长沙 410001
  • 收稿日期:2012-06-23 修回日期:2013-07-29 出版日期:2013-07-25 发布日期:2013-07-29
  • 作者简介:伍树芝,女,1963年生,副主任技师,主要从事临床生化实验诊断研究。
  • 基金资助:

    湖南省自然科学基金计划项目(10JJ5021)

The significance of serum NT-proBNP for the future risk evaluation of major adverse cardiac events in elderly patients with stable coronary artery disease

WU Shuzhi   

  1. Department of Clinical Laboratory, Geriatric Hospital, Hunan Changsha 410001,China
  • Received:2012-06-23 Revised:2013-07-29 Online:2013-07-25 Published:2013-07-29

摘要: 目的 探讨氨基末端B型钠尿肽原(NT-proBNP)对老年稳定型冠心病(SCAD)患者未来主要不良心脏事件(MACE)风险评估的价值。方法 将810例老年SCAD患者按随访期内病情转归情况分为非MACE组468例、MACE组342例(包括心源性再入院组200例、非致死急性心肌梗死(AMI)组61例、死亡组81例);按MACE发生时间顺序分为近期MACE组180例和远期 MACE 组162 例。采用双向侧流免疫法检测所有入选患者和 40名健康对照者以及入选患者随访期间的第 3个月、第 6个月及第12个月血清NT-proBNP水平,并进行统计学分析。对患者平均随访24个月,观察随访期间发生的MACE。结果 初次住院时,MACE组及非MACE组NT-proBNP水平明显高于对照组(P<0.01);MACE组NT-proBNP水平高于非 MACE 组(P<0.01),近期 MACE 组高于远期MACE组(P<0.05);死亡组及非致死 AMI 组NT-proBNP水平明显高于再入院组(P<0.05)。且NT-proBNP水平与患者再入院和发生AMI的时间呈负相关[r 值分别为-0.359(P=0.00)、-0.458(P=0.026)]。随着NT-proBNP水平的增高,不同NT-proBNP 水平组的MACE 发生率相应增高,除NT-proBNP>6 000 ng/L组外,其余各组MACE 发生率差异有统计学意义(P<0.01)。MACE组发生MACE 前的 NT-proBNP 峰值水平明显高于非 MACE 组。死亡组 NT-proBNP 峰值水平明显高于其他组 (P<0.05、P<0.01)。在随访第3个月、第6个月及第12个月,MACE 组NT-proBNP水平均高于初次进院时(P<0.01);非MACE组患者NT-proBNP水平明显低于初次进院时(P<0.01),亦明显低于MACE 组(P<0.01)。Kaplan-Meier曲线分析表明,不同NT-proBNP水平组患者的生存率差异有统计学意义(P<0.01)。合并不同疾病死亡组患者血清NT-proBNP水平比较差异无统计学意义(P>0.05)。结论 老年SCAD 患者未来 MACE发生率及其发生时间与初入院时NT-proBNP水平、随访期内NT-proBNP动态变化及其峰值水平密切相关。NT-proBNP检测对老年SCAD未来 MACE风险评估有较高的预测价值。

关键词: 氨基末端B型钠尿肽原, 老年稳定型冠心病, 主要不良心脏事件

Abstract: Objective To investigate the significance of serum N-terminal pro-B-type natriuretic peptide (NT-proBNP)for the future risk evaluation of major adverse cardiac events (MACE) in elderly patients with stable coronary artery disease (SCAD). Methods A total of 810 elderly patients with SCAD were classified into non-MACE group(468 cases) and MACE group [342 cases, including cardiogenic readmission group (200 cases), nonfatal acute myocardial infarction (AMI) group(61 cases) and death group(81 cases)] according to disease prognosis. The 342 cases of MACE group were classified into the short-term MACE group(180 cases)and the long-term MACE group(162 cases). The serum NT-proBNP levels of 40 healthy controls and 810 elderly patients with SCAD, which were followed up in the third month, in the sixth month and in the twelfth month, were determined by bi-directional lateral flow immunoassay. The results were analyzed statistically. The MACE were followed up and observed for an average of 24 months. Results The serum NT-proBNP levels at initial admission in the MACE group and non-MACE group were significantly higher than those in the control group(P<0.01),the serum NT-proBNP levels at initial admission in the MACE group were significantly higher than those in the non-MACE group (P<0.01), the serum NT-proBNP levels at initial admission in the short-term MACE group were significantly higher than those in the long-term MACE group (P<0.05), and the serum NT-proBNP level at initial admission in the death group and nonfatal AMI group were significantly higher than those in the cardiogenic readmission group (P<0.05). The serum NT-proBNP levels at initial admission were negatively correlated with the interval time of the patients with readmission and AMI [r=-0.359(P=0.000),r=-0.458(P=0.026)]. The serum NT-proBNP level was higher,and the incidence rates of MACE were higher. The incidence rates of MACE in different serum NT-proBNP level groups were significantly different (P<0.01), except the NT-proBNP>6 000 ng/L group. Before MACE, the top value of serum NT-proBNP in the MACE group was significantly higher than that in the non-MACE group, and the top value of serum NT-proBNP in the death group was significantly higher than that in the other groups (P<0.05, P<0.01). In the third, sixth and twelfth months of follow-up period, the serum NT-proBNP levels in the MACE group were significantly higher than those at initial admission(P<0.01). The serum NT-proBNP levels in the non-MACE group were significantly lower than those at initial admission(P<0.01), and were significantly lower than those in MACE group(P<0.01). Kaplan-Meier curve showed that the survival rate with different serum NT-proBNP levels had statistical significance (P<0.01). The death group with various diseases had no statistical significance for the serum NT-proBNP levels (P>0.05). Conclusions The incidence rate of MACE and the interval time of the MACE in elderly patients with SCAD are closely correlated with the serum NT-proBNP level at initial admission and with the changes of serum NT-proBNP levels and the top value of serum NT-proBNP in the follow-up period. The serum NT-proBNP determination for the MACE risk evaluation in elderly patients with SCAD has an important prognostic significance.

Key words: N-terminal pro-B-type natriuretic peptide, Elderly stable coronary artery disease, Major adverse cardiac event

中图分类号: